Extended Follow-Up After Wearable Cardioverter-Defibrillator Period: The PROLONG-II Study

Johanna Müller‐Leisse; Johanna Brunn; Christos Zormpas; Stephan Hohmann; Henrike A. K. Hillmann; Jörg Eiringhaus; Johann Bauersachs; Christian Veltmann; David Duncker

doi:10.1002/ehf2.13586

September 4, 2021SHILAP Revista de lepidopterologíaOpen Access

Extended Follow-Up After Wearable Cardioverter-Defibrillator Period: The PROLONG-II Study

View Full Paper

Ask AI

Bookmark

Share

Figures

Why the study?

Does careful risk stratification after wearable cardioverter-defibrillator (WCD) prescription safely identify patients who do not need an ICD?

Key Points

To evaluate long-term survival and sudden cardiac death incidence in patients following temporary wearable cardioverter-defibrillator use and subsequent risk stratification.
Assessed long-term clinical outcomes during extended follow-up after wearable cardioverter-defibrillator (WCD) prescription in the PROLONG-II study.
Tracked survival in patients who received WCD shocks and monitored sudden cardiac death incidence in patients who did not receive an implantable cardioverter-defibrillator (ICD) indication after WCD wear.
Patients who experienced appropriate WCD shock delivery demonstrated favorable overall survival during extended follow-up.
Patients deemed not to require an ICD recommendation following the WCD prescription period experienced no sudden cardiac deaths during follow-up.

Structured PICO

Does careful risk stratification after wearable cardioverter-defibrillator (WCD) prescription safely identify patients who do not need an ICD?

P

Population

Patients prescribed a wearable cardioverter-defibrillator (WCD)

I

Intervention

Wearable cardioverter-defibrillator (WCD) prescription and subsequent risk stratification for ICD

O

Outcome

Survival and sudden cardiac death (SCD) during follow-uphard clinical

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Careful risk stratification after a period of WCD use is safe, as patients not recommended for an ICD experienced no sudden cardiac death during follow-up.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Müller‐Leisse et al. (2021) studied this question.

synapsesocial.com/papers/69d77904b843b2be9948fede https://doi.org/10.1002/ehf2.13586

View Full Paper

Ask AI

Bookmark

Share

Extended Follow-Up After Wearable Cardioverter-Defibrillator Period: The PROLONG-II Study

Figures

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Extended Follow-Up After Wearable Cardioverter-Defibrillator Period: The PROLONG-II Study

Figures

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading